Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for use in medically supervised settings. The company's mission is to support healthcare providers by delivering advanced care solutions to patients. Headquartered in San Mateo, California, Talphera focuses on addressing unmet medical needs within critical care environments.

Key product candidates in Talphera's portfolio include Niyad® (nafamostat mesylate), a lyophilized formulation of nafamostat, which is being investigated as a regional anticoagulant for the extracorporeal circuit in adult patients undergoing continuous renal replacement therapy (CRRT). Niyad has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The company is also developing LTX-608, another nafamostat formulation for direct IV infusion with potential applications in conditions such as acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC), as well as pre-filled syringe product candidates like Fedsyra™ (ephedrine) and phenylephrine. Talphera divested its DSUVIA drug to Alora Pharmaceuticals in March 2024, narrowing its focus to its current pipeline.

Under the leadership of CEO Vincent J. Angotti, Talphera rebranded from AcelRx Pharmaceuticals, Inc. in January 2024 to reflect its expanded strategic focus beyond acute pain management. Recent corporate updates include reaching the 50% enrollment milestone in the NEPHRO CRRT study for Niyad in March 2026, with study completion anticipated later in 2026. The company also announced its first quarter 2026 financial results in May 2026.